- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Omnicell Inc(OMCL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OMCL
11/20/2026: OMCL (1-star) is a SELL. SELL for 5 days. Simulated Profits (-1.42%). Updated daily EoD!
Omnicell Inc is a healthcare technology company that designs automated medication management systems, robotics, and cloud software for hospitals and pharmacies. The company's primary strengths lie in its extensive installed base and comprehensive Autonomous Pharmacy product ecosystem, which help health systems reduce medication administration errors. Its main growth opportunity centers on expanding high-margin recurring SaaS subscriptions and rolling out next-generation platforms like Titan XT. Key risks include hospital capital expenditure cyclicality and intense competition from major medical technology rivals such as Becton Dickinson. The stock suits growth-oriented healthcare investors willing to monitor quarterly booking trends and hospital spending cycles.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While the Autonomous Pharmacy transition offers secular growth, near-term revenue expansion has occasionally tracked hospital capital spending cycles. |
| Momentum investor | Strong fit while signal remains positive | Momentum alignment is conditional on sustained positive quarterly product booking beats and upward revisions to recurring revenue guidance. |
| Value investor | Mixed fit | Valuation can look attractive following pullbacks, but low GAAP profitability requires close scrutiny of operating leverage. |
| Dividend investor | Weak fit | Omnicell does not pay a cash dividend, focusing its capital allocation strategy entirely on business reinvestment. |
| Low-risk investor | Weak fit | The stock experiences notable price volatility tied to healthcare sector sentiment and hospital equipment spending trends. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock frequently reacts sharply to quarterly product booking updates and shifting hospital capital budgets. |
| Valuation risk | Medium | Valuation multiples can fluctuate widely depending on cyclical swings between GAAP earnings and non-GAAP cash flows. |
| Competition risk (Becton Dickinson) | High | Intense rivalry with larger incumbents like BD and its Pyxis platform can pressure pricing power and tender win rates. |
| Business quality | Medium / high | High customer retention and a growing SaaS recurring revenue base provide solid structural characteristics. |
| Dividend income | Low / none | Income-focused investors receive no cash return from dividends as earnings are retained for growth. |
| Execution risk | Medium / high | Successful execution of the Titan XT rollout and SaaS subscription expansion is critical to achieving long-term margin targets. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.50B USD | Price to earnings Ratio 33.86 | 1Y Target Price 57.43 |
Price to earnings Ratio 33.86 | 1Y Target Price 57.43 | ||
Volume (30-day avg) 558.8K shares | Beta 0.89 | 52 Weeks Range 31.75 - 55.00 | Updated Date 11/21/2026 |
52 Weeks Range 31.75 - 55.00 | Updated Date 11/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.96 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Health Information Services
- BUY participation
- 100.0%
- Active BUY / eligible
- 2 / 2
- 30-Day BUY Count Change
- 0
Eligible universe: 2 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -17.1% | Avg. Invested days 35 | Today’s Advisory SELL |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Connected Devices and Software Licenses | Sales of automated dispensing cabinets, Titan XT systems, pharmacy robotics, and associated software licenses. | Represents primary hardware deployment revenue booked upon installation. |
| Technical Services | Field service maintenance, hardware upkeep, and implementation support. | Provides stable, recurring post-installation support cash flows. |
| SaaS and Expert Services | Subscription software, EnlivenHealth analytics, and specialty pharmacy management services. | High-margin recurring revenue stream underpinning long-term valuation health. |
| Consumables | Specialized medication adherence packaging cards and consumable supplies. | Steady repeat product sales tied directly to ongoing customer utilization. |
| Geography (North America & International) | Hospital and health system sales concentrated primarily in the United States and Canada. | Sales exposure is heavily tied to domestic healthcare infrastructure spending trends. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 0.24 | Actual 0.36 |
Profitability
Profit Margin 3.59% | Operating Margin (TTM) 4.6% |
Management Effectiveness
Return on Assets (TTM) 1.78% | Return on Equity (TTM) 3.52% |
Valuation
Trailing PE 33.86 | Forward PE 29.5 | Enterprise Value 1.41B | Price to Sales(TTM) 1.2 |
Enterprise Value 1.41B | Price to Sales(TTM) 1.2 | ||
Enterprise Value to Revenue 1.14 | Enterprise Value to EBITDA 9.54 | Shares Outstanding 46.00M | Shares Floating 44.69M |
Shares Outstanding 46.00M | Shares Floating 44.69M | ||
Percent Insiders 2.07 | Percent Institutions 106.92 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

